Cardobis M2.5 mg+5 mg

Cardobis M 2.5 mg+5 mg is a fixed-dose combination antihypertensive indicated for:

• Hypertension: Treatment of high blood pressure in adult patients whose blood pressure is not adequately controlled on monotherapy with either a beta-blocker or a calcium channel blocker alone, and in patients likely to need more than one drug to reach their blood pressure goal. Cardobis M 2.5 mg+5 mg is not indicated for initial therapy of hypertension.
• Adjunct in chronic stable angina (where clinically appropriate): Because both the beta-blocker and calcium channel blocker components have anti-anginal activity, Cardobis M 2.5 mg+5 mg may be used, under physician supervision, as part of the management of chronic stable angina in hypertensive patients who also have angina, when combination therapy with these two drug classes is already indicated.

Use of Cardobis M 2.5 mg+5 mg should be individualized by a physician based on blood pressure response and tolerability of each component.

Each tablet of Cardobis M 2.5 mg+5 mg contains bisoprolol fumarate (a beta-1 selective adrenergic blocking agent) and amlodipine (as amlodipine besylate/besilate, a dihydropyridine calcium channel blocker) in fixed-dose strengths such as 5 mg/5 mg or 5 mg/10 mg, depending on the manufacturer's formulation. Exact strength combinations vary by brand; refer to the specific product label for the strength dispensed.

Cardobis M 2.5 mg+5 mg is a fixed-dose combination oral tablet that brings together two complementary classes of antihypertensive medicine in a single dosage form. Bisoprolol fumarate is a cardioselective beta-1 adrenergic receptor blocker, and amlodipine is a long-acting dihydropyridine calcium channel blocker. Combining agents from these two different classes allows blood pressure to be controlled through two distinct mechanisms, often achieving better blood pressure control than increasing the dose of either single agent. Cardobis M 2.5 mg+5 mg is taken once daily and is intended for long-term management of hypertension under regular medical supervision.

Cardobis M 2.5 mg+5 mg belongs to the therapeutic class of combination antihypertensive agents, specifically a cardioselective beta-1 blocker combined with a dihydropyridine calcium channel blocker. It is classified under fixed-dose combination antihypertensives used for the management of essential hypertension.

Cardobis M 2.5 mg+5 mg combines two agents with complementary but distinct mechanisms of blood pressure lowering.

Bisoprolol component

Bisoprolol is a highly beta-1 selective adrenergic receptor blocker. At therapeutic doses it competitively blocks beta-1 receptors predominantly in cardiac tissue, reducing heart rate, myocardial contractility, and cardiac output, and suppressing renin release from the kidney. These effects lower blood pressure and reduce myocardial oxygen demand.

Amlodipine component

Amlodipine is a long-acting dihydropyridine calcium channel blocker. It inhibits transmembrane calcium ion influx into vascular smooth muscle and cardiac muscle by blocking L-type calcium channels, producing relaxation of vascular smooth muscle (predominantly arterial) and a reduction in peripheral vascular resistance, with a gradual onset of action and a long plasma half-life allowing once-daily dosing.

Pharmacokinetically, both components are well absorbed orally; bisoprolol reaches peak plasma concentration in 2-4 hours with an elimination half-life of about 9-12 hours, while amlodipine reaches peak plasma concentration in 6-12 hours with an elimination half-life of approximately 30-50 hours. Bisoprolol is eliminated by combined renal and hepatic routes, while amlodipine is extensively metabolized in the liver.

Cardobis M 2.5 mg+5 mg is taken orally, once daily, at approximately the same time each day, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed unless a physician or pharmacist specifically advises otherwise. Blood pressure should be monitored regularly while taking Cardobis M 2.5 mg+5 mg. The beta-blocker component must never be stopped abruptly (see Precautions and Warnings); any change or discontinuation should be done gradually under medical supervision.

Cardobis M 2.5 mg+5 mg has clinically significant interactions with the following:

• Other beta-blockers: Concomitant use with other beta-adrenergic blocking agents (including ophthalmic beta-blockers) should generally be avoided due to additive bradycardia and hypotension.
• Non-dihydropyridine calcium channel blockers (verapamil, diltiazem): Combining these with the bisoprolol component of Cardobis M 2.5 mg+5 mg can cause additive negative effects on heart rate, AV conduction, and contractility, risking severe bradycardia or heart block; concurrent use requires careful monitoring.
• Clonidine: If clonidine and Cardobis M 2.5 mg+5 mg are used together and both need to be stopped, clonidine should be withdrawn several days after discontinuing the beta-blocker component, to avoid rebound hypertension.
• Antidiabetic agents (insulin, sulfonylureas): The bisoprolol component may mask key symptoms of hypoglycemia, such as tachycardia and tremor; blood glucose should be monitored more closely.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin): May increase plasma levels of the amlodipine component, increasing the risk of hypotension and edema.
• Simvastatin: The amlodipine component increases simvastatin exposure; simvastatin dose should not exceed 20 mg daily in patients taking Cardobis M 2.5 mg+5 mg.
• NSAIDs: May reduce the antihypertensive effect of both components through sodium/fluid retention and prostaglandin inhibition.
• Other antihypertensives/diuretics: May produce additive blood-pressure-lowering effects, increasing risk of symptomatic hypotension.

Always inform the physician or pharmacist of all other medicines being taken before starting Cardobis M 2.5 mg+5 mg.

Side effects of Cardobis M 2.5 mg+5 mg arise from its two components.

Common

• Peripheral edema (ankle/leg swelling), primarily from the amlodipine component
• Fatigue and tiredness
• Dizziness or light-headedness
• Headache
• Flushing
• Bradycardia (slow heart rate)
• Palpitations

Less Common/Serious

• Symptomatic hypotension
• Worsening of heart failure symptoms (shortness of breath, weight gain, edema)
• Cold extremities/worsening of peripheral vascular symptoms
• Bronchospasm (more likely in patients with reactive airway disease)
• Mood changes, sleep disturbance
• Gingival hyperplasia (rare, with prolonged amlodipine use)

Patients should seek prompt medical advice for severe dizziness, fainting, very slow heart rate, chest pain, or marked swelling while taking Cardobis M 2.5 mg+5 mg.

Pregnancy: Cardobis M 2.5 mg+5 mg should be used during pregnancy only if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus. Beta-blockers, including bisoprolol, can cause fetal/neonatal bradycardia, hypotension, and hypoglycemia if used in the third trimester; data on amlodipine in human pregnancy are limited. A physician should be consulted before use in pregnancy or if pregnancy is suspected while taking Cardobis M 2.5 mg+5 mg.

Lactation: Both bisoprolol and amlodipine pass into breast milk in small amounts. Cardobis M 2.5 mg+5 mg should be used during breastfeeding only under medical advice, weighing the benefits of treatment against possible effects on the nursing infant, with the infant monitored for signs of beta-blockade (poor feeding, lethargy, bradycardia) if used.

Do not stop abruptly: The bisoprolol component of Cardobis M 2.5 mg+5 mg must not be discontinued suddenly, particularly in patients with coronary artery disease, as abrupt withdrawal can precipitate rebound hypertension, worsening angina, myocardial infarction, or ventricular arrhythmias. Dose should be tapered gradually over 1-2 weeks under medical supervision.

Diabetes: The bisoprolol component may mask signs of hypoglycemia (tachycardia, tremor); blood glucose should be monitored more closely in diabetic patients on Cardobis M 2.5 mg+5 mg.

Heart failure/cardiac disease: Use with caution in patients with compensated heart failure, and avoid in decompensated failure (see Contraindications). Worsening heart failure signs should be reported promptly.

Peripheral vascular disease/Raynaud phenomenon: Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency.

Bronchospastic disease (asthma/COPD): Even cardioselective beta-blockers such as the bisoprolol component can occasionally provoke bronchospasm; use with caution and only if no suitable alternative exists.

Thyrotoxicosis: Beta-blockade may mask signs of hyperthyroidism (e.g., tachycardia); abrupt withdrawal may precipitate thyroid storm.

Anesthesia/surgery: Inform the anesthesiologist that the patient is taking Cardobis M 2.5 mg+5 mg prior to any surgery, as continued beta-blockade affects the heart's ability to respond to reflex stimuli.

Severe hepatic impairment: Use with caution and at the lowest effective dose, with close monitoring, given reduced clearance of the amlodipine component.

Driving/operating machinery: Cardobis M 2.5 mg+5 mg may cause dizziness or fatigue; caution is advised, especially when starting treatment or increasing the dose.

Overdose with Cardobis M 2.5 mg+5 mg can cause severe hypotension, marked bradycardia, cardiac conduction disturbances (including heart block), cardiogenic shock, cardiac arrest, bronchospasm, and hypoglycemia. Excessive peripheral vasodilation from the amlodipine component may cause profound and prolonged hypotension. Any suspected overdose of Cardobis M 2.5 mg+5 mg is a medical emergency - seek immediate medical attention or contact a poison control center/emergency services right away. Management must be carried out in a hospital setting under close cardiac monitoring; do not attempt to treat an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly

No overall dose adjustment is generally required in elderly patients, but they may be more sensitive to the blood-pressure-lowering and heart-rate-lowering effects of Cardobis M 2.5 mg+5 mg; start at the lowest dose and titrate slowly.

Renal Impairment

Use with caution; the bisoprolol component may need dose reduction in significant renal impairment. See Dosage and Administration.

Hepatic Impairment

Use with caution at the lowest starting dose; see Dosage and Administration.

Pediatric

Not recommended; safety and efficacy not established (see Pediatric Uses).

Pregnancy and Lactation

See Pregnancy and Lactation section.

Cardobis M 2.5 mg+5 mg is generally used long-term, often for months to years, as part of ongoing management of chronic hypertension. It should be continued for as long as the treating physician advises, with periodic review of blood pressure control and side effects. It should not be stopped abruptly without medical advice (see Precautions and Warnings).

Beta-1 selective adrenergic blocker (bisoprolol) combined with a dihydropyridine calcium channel blocker (amlodipine); combination antihypertensive.

Cardobis M 2.5 mg+5 mg lowers blood pressure through two mechanisms acting together: bisoprolol selectively blocks cardiac beta-1 adrenergic receptors to reduce heart rate and cardiac output, while amlodipine blocks L-type calcium channels in vascular smooth muscle to produce arterial vasodilation and reduce peripheral resistance. The combined effect produces a greater antihypertensive response than either agent alone at comparable doses.

C

The safety and efficacy of Cardobis M 2.5 mg+5 mg have not been established in children and adolescents under 18 years of age. Use in this population is not recommended. Hypertension in children, when present, should be evaluated and managed by a pediatric specialist using age-appropriate, individually titrated therapy rather than fixed-dose adult combination products such as Cardobis M 2.5 mg+5 mg.